BioSpace News Archive

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for valbenazine as a treatment for Huntington disease (HD). The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation.

Athira Pharma, Inc. announced the company’s financial results for the quarter ended March 31, 2022 and provided pipeline and business updates.

Imago BioSciences, Inc. reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

NexImmune, Inc. reported financial results for the first quarter of 2022.

NeuroPace, Inc. reported financial results for the quarter ending March 31, 2022.

Dyadic International, Inc., a global biotechnology company focused on further improving, applying, and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics announced its financial results for the first quarter of 2022, and highlighted recent company developments.

Angion Biomedica Corp. announced participation in an upcoming investment conference.

Biotechnology company Zymergen Inc., reported preliminary financial results for the first quarter ended March 31, 2022.

Mustang Bio, Inc. announced financial results and recent corporate highlights for the first quarter ended March 31, 2022.

Brickell Biotech, Inc. announced financial results for the first quarter ended March 31, 2022 and provided a corporate update.